New hope for tough cancers: first patients to receive experimental drug
NCT ID NCT06126666
Summary
This is the first time a new drug called ABL103 is being tested in people. The main goal is to find a safe and tolerable dose for adults with advanced solid tumors that have gotten worse despite standard treatments. The study will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, Seoul, 13620, South Korea
Contact
Contact Email: •••••@•••••
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, Seoul, 03080, South Korea
Contact Email: •••••@•••••
-
Sevrance Hospital
RECRUITINGSeoul, South Korea, 03722, South Korea
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.